Biocon's Oral Insulin Fails To Meet Primary Endpoint; Unfazed, Company Says Stage Set For Partnering Talks With Global Pharma
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - India's flagship biotechnology company Biocon suffered a significant setback to its most ambitious research project - an orally delivered insulin - that failed to meet its primary end point of lowering HbA1c levels by 0.7 percent in a clinical study concluded recently in India